share_log

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

大摩資源lof維持Blueprint Medicines等權重,並將目標價格提高至115美元。
Benzinga ·  07/12 13:18

Morgan Stanley analyst Michael Ulz maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $110 to $115.

大摩資源lof的分析師Michael Ulz認爲Blueprint Medicines (納斯達克:BPMC) 評級爲等權重並將目標價從110美元上調至115美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論